View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 4, 2020

Iktos and SRI to use AI for Covid-19 drug development

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Artificial intelligence (AI) technology provider Iktos and research centre SRI International have partnered to discover and develop drugs to treat various viruses, including the novel coronavirus that causes Covid-19 and influenza.

Iktos will combine its generative modelling technology with SRI’s fully automated synthetic chemistry platform called SynFini to design compounds and speed-up the identification of drug candidates.

The Iktos AI technology leverages deep generative models for the accelerated drug discovery process, made possible via the automatic design of virtual molecules with the required characteristics of a new drug candidate.

Iktos co-founder and CEO Yann Gaston-Mathé said: “Iktos generative AI technology has proven its value and potential to accelerate drug discovery programs in multiple collaborations with renowned pharmaceutical companies.

“We are eager to apply it to SRI’s endonuclease programme and hope our collaboration can make a difference and speed up the identification of promising new therapeutic option for the treatment of Covid-19.”

The SynFini platform is intended to speed-up chemical discovery and development, advancing drugs to the clinic quickly and affordably, said SRI.

The closed-loop platform is said to automate the design, reaction screening and optimisation (RSO), as well as generation of target molecules.

SRI’s ongoing programme is working towards drugs that can block endonuclease enzymes, known to be prevalent to several viruses.

These enzymes are associated with viral replication and inhibition of host resistance to infection.

Covid-19 sequence analysis suggests the presence of an endonuclease that it is nearly 97% genetically similar to the SARS virus.

According to findings from recent studies, inhibition of the SARS virus endonuclease blocks the virus’ pathogenesis, said to demonstrate a 100% survival rate in preclinical models.

Based on research, Covid-19 endonuclease should be a beneficial therapeutic target.


Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology